COMP <GO>
CTMX vs EOLS // RETURN ON INVESTED CAPITAL (ROIC)
CytomX Therapeutics Inc. (NASDAQ) VS. Evolus Inc. (NASDAQ) • 15-METRIC TALLY: CTMX 2
— EOLS 6
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: CTMX
LAST: $2.34 (+2.18%) • MKT CAP: $499.0M
roic
-20.50%
LAST: $7.35 (-2.26%) • MKT CAP: $496.7M
roic
-35.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTMX VS. EOLS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CTMX | EOLS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 66.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -20.50% | -35.00% | +14.50 | CTMX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -15.19% | -9.20% | -5.99 | EOLS | /fcf-yield <GO> |
| Operating Margin | -29.30% | -11.00% | -18.30 | EOLS | /operating-margins <GO> |
| Net Profit Margin | -22.80% | -17.40% | -5.40 | EOLS | /net-margins <GO> |
| Revenue Growth (YoY) | -44.80% | 11.60% | -56.40 | EOLS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 4/9 | -3.00 | EOLS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.9 | 49.6 | -8.70 | EOLS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $499.0M | $496.7M | $2.3M | CTMX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CTMX REV | EOLS REV | CTMX GROSS % | EOLS GROSS % | CTMX FCF | EOLS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $76.2M | $297.2M | — | 66.3% | -$75.8M | -$45.7M |
| FY 2024 | $138.1M | $266.3M | — | 68.5% | -$86.5M | -$19.5M |
| FY 2023 | $101.2M | $202.1M | — | — | -$56.0M | -$34.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTMX // BETA —
EOLS // BETA —